Paper · 41372167
SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress.
Coleman KE and 7 others. Nat Commun, 2025. Cited by 4 papers, by iCite.
11 sourcespapers-2026-11-12-0.1.0
Cite this record
ConductScience Library. SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress. Papers, record 41372167. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41372167
On this page
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- SLFN11 counteracts the RFWD3-PRIMPOL DNA damage tolerance axis to restrain gapped DNA synthesis in response to replication stress.
- PubMed
Topics10
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| DNA Damage | Major topic |
| DNA Replication | Major topic |
| DNA-Directed DNA Polymerase | Major topic |
| DNA Primase | Major topic |
| Multifunctional Enzymes | Major topic |
| Ubiquitin-Protein Ligases | Major topic |
| Nuclear Proteins | Major topic |
| Humans | |
| DNA | |
| DNA Damage Tolerance |
Source PubMed
Grants10
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by | Source |
|---|---|---|---|---|---|
| P30 CA016087 | NCI NIH HHS | United States | P30CA016087 | PubMed and NIH | NIH RePORTER |
| P01CA288368 | U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) | P01CA288368 | PubMed and NIH | NIH RePORTER | |
| R35 GM139610 | NIGMS NIH HHS | United States | R35GM139610 | PubMed and NIH | NIH RePORTER |
| P01 CA288368 | NCI NIH HHS | United States | P01CA288368 | PubMed and NIH | NIH RePORTER |
| R35 GM134947 | NIGMS NIH HHS | United States | R35GM134947 | PubMed and NIH | NIH RePORTER |
| ES031658 | U.S. Department of Health & Human Services | NIH | National Institute of Environmental Health Sciences (NIEHS) | R01ES031658 | PubMed and NIH | NIH RePORTER | |
| R01 AI153040 | NIAID NIH HHS | United States | R01AI153040 | PubMed and NIH | NIH RePORTER |
| R01 ES031658 | NIEHS NIH HHS | United States | R01ES031658 | PubMed and NIH | NIH RePORTER |
| P01 CA247773 | NCI NIH HHS | United States | P01CA247773 | PubMed and NIH | NIH RePORTER |
| GM139610 | U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (NIGMS) | R35GM139610 | PubMed and NIH | NIH RePORTER |
Trials0
The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.
None in this release.
Comments and corrections0
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
None in this release.
References98
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 34,624,216 | Temporally distinct post-replicative repair mechanisms fill PRIMPOL-dependent ssDNA gaps in human cells. | Mol Cell | 2021 | https://conductscience.org/library/papers/34624216 | PubMed |
| 2 | 32,391,871 | E3 ligase RFWD3 is a novel modulator of stalled fork stability in BRCA2-deficient cells. | J Cell Biol | 2020 | https://conductscience.org/library/papers/32391871 | PubMed |
| 3 | 31,676,232 | PRIMPOL-Mediated Adaptive Response Suppresses Replication Fork Reversal in BRCA-Deficient Cells. | Mol Cell | 2020 | https://conductscience.org/library/papers/31676232 | PubMed |
| 4 | 38,875,319 | Schlafen 11 triggers innate immune responses through its ribonuclease activity upon detection of single-stranded DNA. | Sci Immunol | 2024 | https://conductscience.org/library/papers/38875319 | PubMed |
| 5 | 38,502,677 | SMARCAL1 ubiquitylation controls its association with RPA-coated ssDNA and promotes replication fork stability. | PLoS Biol | 2024 | https://conductscience.org/library/papers/38502677 | PubMed |
| 6 | 38,058,754 | Further Evidence for RFWD3 Gene Causing Fanconi Anemia Complementation Group W: Detailed Clinical Report of the Second Case in the Literature. | Mol Syndromol | 2023 | https://conductscience.org/library/papers/38058754 | PubMed |
| 7 | 33,863,777 | SLFN11 Inactivation Induces Proteotoxic Stress and Sensitizes Cancer Cells to Ubiquitin Activating Enzyme Inhibitor TAK-243. | Cancer Res | 2021 | https://conductscience.org/library/papers/33863777 | PubMed |
| 8 | 34,508,659 | REV1-Polζ maintains the viability of homologous recombination-deficient cancer cells through mutagenic repair of PRIMPOL-dependent ssDNA gaps. | Mol Cell | 2021 | https://conductscience.org/library/papers/34508659 | PubMed |
| 9 | 23,341,130 | A novel small molecule RAD51 inactivator overcomes imatinib-resistance in chronic myeloid leukaemia. | EMBO Mol Med | 2013 | https://conductscience.org/library/papers/23341130 | PubMed |
| 10 | 30,753,225 | SLFN11 can sensitize tumor cells towards IFN-γ-mediated T cell killing. | PLoS One | 2019 | https://conductscience.org/library/papers/30753225 | PubMed |
1 to 10 of 98
See all 98 referencesCited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 4 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42,909,555 | DPP9 modulates RPA1 stability and temozolomide sensitivity through RFWD3 Nuclear localization in glioma. | Cell Oncol (Dordr) | 2026 | https://conductscience.org/library/papers/42909555 | PubMed |
| 42,615,306 | RFWD3: A pivotal E3 ubiquitin ligase in DNA damage response, non-neoplastic disorders and multi-system tumorigenesis. | Sci Prog | 2026 | https://conductscience.org/library/papers/42615306 | PubMed |
| 42,215,448 | PHF20 stabilizes the GAS7-F-actin axis to drive DNA damage repair and chemoresistance in cutaneous squamous cell carcinoma. | Cell Death Dis | 2026 | https://conductscience.org/library/papers/42215448 | PubMed |
| 42,098,304 | SLX4IP limits replication stress globally and at ALT telomeres. | EMBO J | 2026 | https://conductscience.org/library/papers/42098304 | PubMed |
| 42,092,629 | Molecular Determinants of Response and Rational Drug Combinations for Antibody-Drug Conjugates (ADCs) with Topoisomerase I (TOP1) Inhibitor Payloads. | J Mol Biol | 2026 | https://conductscience.org/library/papers/42092629 | PubMed |
| 41,991,718 | Topoisomerase I inhibitor antibody-drug conjugates in breast cancer: the relevance of the DNA damage response to resistance, response, and combination treatment strategies. | Breast Cancer Res Treat | 2026 | https://conductscience.org/library/papers/41991718 | PubMed |
Genes4
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| DNAH8 | 1,769 | PubTator's text mining | https://conductscience.org/library/genes/1769 | NCBI Gene |
| PRIMPOL | 201,973 | PubTator's text mining | https://conductscience.org/library/genes/201973 | NCBI Gene |
| RFWD3 | 55,159 | PubTator's text mining | https://conductscience.org/library/genes/55159 | NCBI Gene |
| SLFN11 | 91,607 | PubTator's text mining | https://conductscience.org/library/genes/91607 | NCBI Gene |
Drugs0
The drugs whose trials, in the Pipelines release, list the paper.
None in this release.
Data0
The data bank entries PubMed's record names. Trial numbers are under Trials.
None in this release.
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/41372167
GET https://conductscience.org/api/papers/v1/41372167/references?page=2